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Monocyte unresponsiveness and impaired
IL1β, TNFα and IL7 production are
associated with a poor outcome in
Malawian adults with pulmonary
tuberculosis
Catriona John Waitt1,2*, Peter Banda3, Sarah Glennie1,4, Beate Kampmann5,6, S. Bertel Squire7,
Munir Pirmohamed2 and Robert Simon Heyderman1,7
Abstract
Background: Early death during TB treatment is associated with depressed TNFα response to antigenic stimulation
and propensity to superadded bacterial infection. Hypothesising the role of monocyte unresponsiveness, we further
compared the immunological profile between patients who died or suffered a life-threatening deterioration ('poor
outcome') during the intensive phase of TB treatment with patients who had an uneventful clinical course (‘good
outcome’) who had been recruited as part of a larger prospective cohort study of Malawian TB patients.
Methods: Using Luminex, IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12, IL13, IL17, GCSF, GMCSF, MCP1, MIP1b, IFNγ and
TNFα were measured in whole blood assay supernatants (stimulated with Mycobacterium tuberculosis H37Rv and
LPS) and serum from 44 Malawian adult TB patients (22 of each outcome) immediately prior to commencing
treatment, after 7 days and on day 56 of TB treatment. Monocyte surface expression of CD14, CD16, TLR2, TLR4,
CD86 and HLADR, and intracellular TNFα were measured by flow cytometry as was intracellular TNFα response to
purified TLR ligands.
Results: Lower TB antigen-induced IL1β (p = 0.006), TNFα (p = 0.02) and IL7 (p = 0.009) were produced in the poor
outcome group. TNFα was produced by ‘classical’ CD14hiCD16lo monocytes, with no correlation between this
response and expression of monocyte surface markers. Response to TB antigens correlated with responses to the
purified TLR 2, 3 and 4 ligands.
Conclusions: Dysregulated monocyte cytokine production was identified in TB patients with poor outcome. Lower
TNFα responses to H37Rv paralleled lower responses to a panel of TLR ligands, suggesting an underlying perturbation
in common TLR signalling pathways. Future work should explore the role of TLR polymorphisms in immune response
and clinical outcome in TB patients.
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Background
The global burden of tuberculosis (TB) remains consid-
erable with an estimated 8.6 million new cases of TB
and 1.3 million deaths in 2012. In a prospective cohort
of 321 Malawian adults, we have recently shown that
12 % of laboratory confirmed pulmonary tuberculosis
(PTB) cases either died or had an adverse event (principally
related to TB or presumed secondary bacterial infection)
during the first two months of treatment. In 50 % of
HIV-negative and 63 % of HIV-positive TB patients, the
cause of self-presentation with a life-threatening clinical
event was a presumed superadded bacterial infection,
with isolation of Streptococcus pneumoniae and Salmon-
ella typhiumurium in a proportion. This poor outcome
was associated with reduced production of the pro-
inflammatory cytokine TNFα in response to stimulation
with heat killed Mycobacterium tuberculosis H37Rv
(H37Rv) and lipopolysaccharide (LPS) [1]. However, the
molecular and cellular processes that underlie this asso-
ciation are unclear.
In acute bacterial sepsis, dysfunctional monocyte re-
sponses have been described where down-regulation of
HLA-DR on CD14+ monocytes [2, 3] correlates with
poor outcome [4] and a propensity for secondary bacterial
infection [2, 4]. Decreased expression of the co-stimulatory
molecule CD86 [5, 6] is also associated with greater sever-
ity of illness and inflammation in severe sepsis [7]. Mono-
cyte recognition of pathogen associated molecular patterns
(PAMPs) including bacterial and mycobacterial antigens
occurs via conserved pathogen recognition receptors,
among which the Toll Like Receptors (TLRs, principally
TLR2, TLR4 and TLR9) have a major role. We therefore
hypothesised that the depressed TNFα production and
the susceptibility to secondary infection seen in our TB
patients might represent an analogous process to that de-
scribed in acute bacterial sepsis, and that inter-individual
variability in TLR signalling might underpin this. We
therefore sought to further characterize the cytokine and
chemokine response profile in our cohort and investigate
the relationship between monocyte immunophenotype,
TLR utilization and clinical outcome.
Methods
Patient populations
This prospective cohort of Malawian pulmonary TB patients
has been previously reported, comprising 199 patients with
microbiologically proven disease (by sputum smear or
culture). Median age was 31 (range 18–69), 61 % were
male, 72 % were sputum smear positive and 60 % were
HIV-positive with a median CD4 count of 150 (IQR
68–346) cells/mm3. [1]. Ethical approval for this study
was granted by the College of Medicine Research Ethics
Committee, University of Malawi (P.04/05/353) and by
the ethics committee of the Liverpool School of Tropical
Medicine (05.41). Written informed consent was obtained
from all participants.
All patients were of Chewa descent, the most prevalent
ethnic group in southern Malawi. Patients were categorised
as ‘poor outcome’ if they died or suffered a life-threatening
clinical deterioration necessitating urgent medical care dur-
ing the two month intensive phase of TB treatment, and
‘good outcome’ if their clinical course was uncomplicated.
The cytokine analysis was conducted on all 22 patients
who suffered a poor outcome matched by age, sex, HIV
status and CD4 count with 22 good outcome patients
(summarized in Table 1).
Following analysis of this cytokine data, monocyte
immunophenotyping and intracellular cytokine staining
assays were performed in real-time in a further cohort of
30 consecutive patients.. The selection of these populations
in relation to the previously published work is summarised
in Fig. 1.
17-plex analysis of antigen-induced and serum cytokines
The whole blood stimulation assay has previously been
reported [1]. In brief, whole blood was dilulated (1:5, v/v)
with serum-free media and stimulated for 16 h with either
heat killed H37Rv or LPS. Supernatants were harvested
and frozen at −80 °C prior to analysis. The antigen-
induced cytokine concentration was calculated by subtract-
ing the background concentration in the unstimulated
control sample. The Bio-Plex Pro Human Cytokine 17-plex
assay (IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12, IL13,
IL17, GCSF, GMCSF, MCP1, MIP1b, IFNγ and TNFα) was
chosen to quantitate the majority of cytokines and che-
mokines with proven major roles in anti-mycobacterial
immunity; other work has utilized the same panel [8].
This was performed according to the manufacturer’s rec-
ommended protocol (BioRad Laboratories, UK). Serum
and stimulated whole blood assay [1] supernatants from
day 0 and day 7 of TB treatment were analyzed to calcu-
late the area under the curve (AUC) for cytokine produc-
tion between these time points in attempt to quantify
cytokine exposure during that time period. Additionally,
to investigate cytokine dynamics throughout the intensive
phase of TB treatment, serum and whole blood assay
supernatants from six of the ten patients who suffered
a life-threatening clinical deterioration and yet recovered
to complete TB treatment were compared with matched
controls on day 56 of TB treatment; matched data were
unavailable for the remaining four patients who recovered
clinically. Luminex data were acquired with a Bio-Plex
System 200 (Bio-Rad, UK) and analyzed using Bio-Plex
Manager 5.0 software (Bio-Rad, UK).
Monocyte immunophenotyping
Whole blood was stained (FITC labelled anti-human
CD16, PE labelled CD86 , PerCP labelled anti-HLA-DR
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Table 1 Key characteristics of cases and controls
Pair Case/Control Clinical Diagnosis Sex HIV CD4 (cells/mm3) BMI (Kg/m2) Sputum
Smear
Sputum
Culture
Day of
Event
1 Case (death) Advanced TB and severe anaemia F Positive 44 17.8 Positive Positive 14
1 Control F Positive 65 17.7 Positive Positive
2 Case (death) Unknown (died at home) F Positive 92 13.4 Positive Positive 31
2 Control F Positive 174 15.6 Negative Positive
3 Case (death) Unknown (died at home) F Positive 333 20.4 Positive Positive 7
3 Control F Positive 305 17.7 Negative Positive
4 Case (recovered) Pneumonia F Positive 362 18.4 Negative Positive 8
4 Control F Positive 344 19.6 Positive Positive
5 Case (death) 1 week postpartum and sudden collapse,
possible pulmonary embolus
F Negative 376 17.0 Positive Positive 6
5 Control F Negative 400 19.5 Positive Positive
6 Case (death) Septic shock, Salmonella typhimurium M Positive 16 14.2 Positive Positive 3
6 Control M Positive 38 19.8 Positive Positive
7 Case (recovered) Severe anaemia M Positive 19 18.4 Positive Positive 11
7 Control M Positive 39 19.0 Positive Positive
8 Case (death) Salmonella typhimurium M Positive 33 17.1 Positive Unavailable 0
8 Control M Positive 72 14.1 Negative Positive
9 Case (death) Unknown (died at home) M Positive 44 16.2 Positive Positive 14
9 Control M Positive 81 16.0 Positive Positive
10 Case (death) Pneumonia M Positive 50 14.7 Positive Positive 20
10 Control M Positive 92 20.6 Positive Positive
11 Case (recovered) Salmonella typhimurium M Positive 77 18.2 Positive Positive 22
11 Control M Positive 93 19.0 Positive Positive
12 Case (recovered) Gastroenteritis and hypovolaemic shock
(Blood culture negative)
M Positive 94 14.5 Positive Positive 28
12 Control M Positive 112 21.6 Negative Positive
13 Case (death) Septic-shock like presentation (Blood
culture negative)
M Positive 96 Positive Positive 1
13 Control M Positive 150 15.3 Positive Positive
14 Case (death) Pneumonia M Positive 105 Positive Positive 40
14 Control M Positive 154 21.1 Positive Positive
15 Case (death) Advanced TB M Positive 173 N/A Positive Unavailable 10
15 Control M Positive 183 20.1 Negative Positive
16 Case (recovered) Severe anaemia M Positive 186 16.1 Positive Positive 28
16 Control M Positive 208 20.9 Positive Positive
17 Case (death) Advanced TB M Positive 200 19.6 Positive Positive 53
17 Control M Positive 368 21.4 Negative Positive
18 Case (recovered) Pneumonia M Negative 356 18.1 Positive Positive 6
18 Control M Negative 325 18.9 Positive Positive
19 Case (recovered) Pneumonia M Positive 399 19.9 Negative Positive 6
19 Control M Positive 388 20.0 Positive Positive
20 Case (recovered) Heptatotoxicity M Negative 403 14.9 Positive Positive 15
20 Control M Negative 431 21.2 Positive Positive
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and APC labelled anti-human CD14 [all BDSA]) and
then incubated for 10 min prior to lysis (FACSLysing So-
lution, BD Biosciences), washing (PBS + 1%BSA, Sigma
Aldrich) and fixation (2 % paraformaldehyde). Samples
were kept refrigerated at 4 °C, protected from the light,
prior to acquisition by flow cytometry (BD FACScalibur,
BD Biosciences, Oxford, UK).
Intracellular cytokine staining
Whole blood was incubated with H37Rv (American Type
Culture Collection [ATCC No. 25618, Rockville, MD]), LPS
(E coli, strain 055.b5 lipopolysaccharide, Sigma Aldrich) or
TLR agonists (ultra pure E coli LPS [tlrl-pelps]- TLR4,
Pam2CSK4 [tlrl-pam2] – TLR2, Pam3CSK4 [tlrl-pms] –
TLR2/1 and Poly(I:C) [tlrl-pic] – TLR 3, Invivogen,
Nottingham, UK) for 18 h with addition of 1 μl Brefeldin
A (Sigma Aldrich) after the initial two hours. Following
lysis, fixation and permeabilization steps (FACSLysing
Solution, Cytofix/Cytoperm and Perm/Wash Buffer, all
BD Biosciences), cells were stained with FITC labelled
anti-human CD14, PE labelled anti-human IL10, PerCP
labelled anti-human HLA-DR and APC labelled anti-
human TNFα for 15 min. Data was acquired using a BD
FACSCalibur (BD Biosciences, Oxford, UK). Monocytes
were identified on the basis of their forward scatter-side
scatter characteristics. A minimum of 100 000 PBMC
events were analysed. The percentage positivity in the
unstimulated control sample was subtracted from the
stimulated samples.
Statistical analysis
Luminex standards with a recovery outside the recom-
mended boundaries of 70 – 130 % were excluded, as were
those with a CV of greater than 15 %. The interpretation of
values outside the detection range of the assay followed
published methodology used in similar patient populations
[9, 10], resulting in exclusion of antigen-induced produc-
tion of IL5, IL6, IL8, MCP1, MIP1b and GMCSF from the
analysis. Analysis therefore focused on the remaining 11
cytokines. Applying the Bonferroni correction for multiple
comparisons gave a p-value for significance of 0.0045.
Table 1 Key characteristics of cases and controls (Continued)
21 Case (recovered) Empyema – Streptococcus pneumoniae M Negative 426 14.8 Positive Positive 38
21 Control M Negative 367 18.1 Positive Positive
22 Case (death) Advanced TB M Negative 532 N/A Positive Unavailable 0
22 Control M Negative 484 19.8 Positive Positive
Fig. 1 Flowchart indicating the relationship of i) the case–control study and ii) the flow cytometry and ICS study in relationship to the parent
study (Waitt et al., JID 2011)
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Flow cytometric data were analysed using FlowJo ver-
sion 7.6.1 for Windows, under the licensing agreement for
researchers in Africa provided by TreeStar Inc. Statistical
analysis of data was performed using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San
Diego California USA, www.graphpad.com).
Comparison of two matched results from an individual
donor used the paired t-test. Analysis of non-parametric
data used the Mann Whitney U test for comparison of
medians. The direction and magnitude of correlation be-
tween responses to TLR ligands followed a normal dis-
tribution and therefore was analyzed by calculating the
Pearson correlation co-efficient, whereas the Spearman
correlation co-efficient described relationships between
cytokine production and cell count which had a skewed
distribution. In these analyses, statistical significance was
present when p < 0.05.
Results
Cytokine and chemokine production in response to
H37Rv and LPS
Patients with poor clinical outcome had trends towards
lower whole blood IL1β (median 196 [IQR 133–308] vs
894 [IQR 498–1368] p = 0.006 for H37Rv; median 630
[IQR 144–1447] vs 1661 [IQR 548–2134] p = 0.05 for LPS),
TNFα (median 4355 [IQR 981–8598] vs 11977 [IQR 6221–
22285] p = 0.02 for H37Rv; median 3512 [IQR 809–4927]
vs 8623 [IQR 3309–19846] p = 0.01 for LPS) and IL7 (me-
dian 3.75 [IQR 0–57] vs 105 [IQR 37 – 479] p = 0.009 for
H37Rv; median 4.64 [IQR 0–61] vs 131 [IQR 18.7 –
349] p = 0.01 for LPS) production in response to both
H37Rv and LPS (Fig. 2) in comparison with patients
who had an uneventful clinical course. No significant
differences were identified in the levels of the other ana-
lytes (IL2, IL4, IL10, IL12, IL13, IL17, GCSF and IFNγ)
measured in response to these agonists (see Additional
file 1: Table S1 for a complete list of analyses performed),
or in any of the panel measured in serum at the same time
points. No statistically significant differences in cytokine
profile were identified between the groups of patients
when assessing the values at commencement of TB treat-
ment alone. Follow-up of patients who survived a life-
threatening deterioration until the end of the 56 day in-
tensive phase of TB treatment revealed a trend towards
restoration of the initially depressed IL1β (p = 0.04) and
TNFα responses (p = 0.18) when compared with con-
trols (Fig. 3).
i) Cellular source of TNFα production
Intracellular cytokine staining monocytes from TB pa-
tients revealed the predominant producer of TNFα in
whole blood to be the ‘classical’ monocyte phenotype, stain-
ing strongly for CD14 and weakly for CD16 (CD14hiCD16lo
monocytes). Although we were able to identify the
CD14loCD16hi cells which have been described in bacterial
sepsis (Additional file 2: Figure S1) [11], the proportion of
these cells producing TNFα in response to stimulation with
H37Rv and LPS was much less (Fig. 4). There was no cor-
relation between total TNFα production and absolute
monocyte count (r= 0.11, p = 0.23 for the response to
H37Rv; r = 0.03, p = 0.70 for the response to LPS).
ii) Monocyte Surface Markers
There was no correlation between monocyte expression
of TLR2, TLR4, HLADR or CD86 with TNFα production
(data not shown).
iii)Response to TLR Ligands
Fig. 2 Cytokine responses to stimulation with H37Rv and LPS, expressed as the area under the concentration time curve (AUC) between Day 0
(immediately prior to commencing treatment) and Day 7 of TB treatment. Patients who had a poor outcome had lower production of TNFα, IL1β
and IL7 compared to matched control patients who had an uneventful clinical course. No significant differences were identified between patient
groups in the other cytokines and chemokines analysed
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Although the expression of TLRs 2 and 4 on the cell
surface was not associated with the magnitude of TNFα
production, there were significant correlations between
production of TNFα in response to H37Rv and LPS and
the purified TLR ligands P3CSK (R2 = 0.78, p < 0.0001 for
H37Rv; R2 = 0.69, p = 0.0001 for LPS), Poly(I:C) (R2 = 0.54,
p = 0.0018 for H37Rv; R2 = 0.66, p = 0.0003 for LPS) and
Ultrapure LPS (R2 = 0.52, p = 0.0024 for H37Rv; R2 = 0.59,
p = 0.0008 for LPS) which act via these receptors and their
downstream pathways (Table 2).
Discussion
Having previously shown that early deaths during tuber-
culosis treatment are associated with depressed innate
immune responses, bacterial infection and tuberculosis
progression, we have now demonstrated this to be a con-
sequence of broad-ranging monocyte hyporesponsiveness
to pathogenic stimulation. In addition to the lower TNFα
in response to both LPS and heat-killed Mycobacterium
Tuberculosis H37Rv already described [1], we noted lower
IL1β and IL7 production in the poor outcome group. IL1β
is a pro-inflammatory cytokine involved in the initial re-
sponse to tuberculosis [12]. Production is suppressed by
IL4 [13] and IL10 [14]; however we did not see changes in
Fig. 3 IL1β and TNFα production in response to stimulation with H37Rv and LPS immediately prior to the start of TB treatment and at the end of
the intensive phase, in 6 patients who had a life-threatening clinical deterioration (poor) with controls matched by age, sex, HIV status and CD4
count who had an uneventful clinical course. There was significant restoration of the depressed IL1β responses in parallel with clinical recovery
(p = 0.04), with a trend towards restoration of TNFα response (0.18)
Fig. 4 TNFα production in response to stimulation with H37Rv and LPS
in ‘classical’ CD14hiCD16lo and CD14loCD16hi monocyte populations. A
significantly greater percentage of CD14hiCD16lo cells produced TNFα in
response to stimulation with H37Rv (p = 0.0002) and LPS (p < 0.0001)
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these regulatory cytokines in our cohort. IL7 is a haemo-
poietic growth factor secreted predominantly by stromal
cells in the bone marrow and thymus, and to a lesser de-
gree keratinocytes, dendritic cells, hepatocytes, neurones
and epithelial cells. It has a key role in T cell homeostasis
with perturbation of the IL7/IL7 receptor axis occurring
with advancing HIV but the biological role of IL7 in pul-
monary tuberculosis is uncertain. Lower levels have been
reported in advanced disease [15] and reduced expression
of IL7Rα was found in patients with active versus latent
disease [16]. Patients who recovered from a life-threatening
event revealed a trend towards recovery in IL1β and TNFα
responses, suggesting the initial dysfunction to be a transi-
ent phenomenon. Analogous to this may be the finding that
endotoxin-tolerant monocytes from patients with severe
sepsis reverted to normal responsiveness following success-
ful treatment, in contrast to cells from patients who died,
which never recovered [17].
We therefore sought to determine whether the mono-
cyte dysfunction in TB mirrored that reported in sepsis.
However, despite some similarities, several important
differences were seen. Firstly, whereas an expanded sub-
set of CD16 monocytes has been described as a major
producer of TNFα in response to stimulation with both
LPS and the TLR ligand P3CSK [11] in patients with bac-
terial sepsis, the expanded population of CD14loCD16hi
cells in TB patients had little functional relevance in terms
of TNFα production. Secondly, in contrast to the
decreased monocyte HLA-DR expression which has
been proposed as a potential prognostic marker in
patients with sepsis [18, 19], we found variable HLA-
DR expression which did not correlate with functional
capacity to produce TNFα or clinical outcome. Whilst
expression of CD86 positively correlated with HLA-DR,
we identified no functional significance of this molecule
in relation to TNFα production.
Not having explained variability in TNFα production
in terms of monocyte surface markers with proven signifi-
cance in bacterial sepsis, we next investigated the contri-
bution of TLR signalling to TNFα response. Among the
TLRs, TLR2, TLR4 and TLR9 have proven roles in the
recognition of, and response to, M tuberculosis. Purified
mycobacterial antigens preferentially interact with TLR2,
in combination with TLR1 and TLR6. However, infection
with whole bacilli evokes a more complex interaction pat-
tern involving at least TLR2 and TLR4 and leads to differ-
ential activation of antibacterial effector pathways, which
is MyD88 signalling dependent [20]; studies investigating
the role of individual TLRs in response to mycobacterial
antigens are not fully conclusive [21]. TLR9, which is
located intracellularly, responds to antigens following
phagocytosis [21]. Ligation of TLRs triggers a cascade
of intracellular events, initiated by the activation of the
adapter molecule MyD88. Finally, translocation of the
transcription factor NFκB to the nucleus provides the
signal for up regulation of cytokines, chemokines and
co-stimulatory molecules which shape the subsequent
development of immune responses. Whilst monocyte
expression of TLRs 2 and 4 during the intensive phase
of TB treatment did not correlate with clinical severity
or overall TNFα production, use of purified TLR ligands
demonstrated reduced functional capacity of these recep-
tors in terms of triggering the expected inflammatory re-
sponse to pathogenic stimulation. The depressed TNFα
production in response to HKH37Rv and LPS paralleled
decreased responses to TLR1, 2, 3, 4 and 6 ligands, sug-
gesting that rather than a pathogen-specific process, a
generalised innate hyporesponsiveness is present. Al-
though many investigators have focussed on the rela-
tionship between specific mycobacterial antigens and
individual TLRs, it has recently been suggested that the
Table 2 Correlation of TNFα responses to TB antigens and TLR
ligands
TLR agonist (18 h) Corresponding TLR receptor
(Spearman’s R and p-value)
Ligand Receptor H37Rv (TB) LPS (bacterial sepsis)
Ultrapure LPS TLR4 0.52, p = 0.0024 0.59, p = 0.0008
Pam2CSK4 TLR2 0.16, not significant 0.38, p = 0.01
Pam3CSK4 TLR1/2 0.78, p < 0.0001 0.69, p = 0.0001
Poly(I:C) TLR3 0.54, p = 0.0018 0.66, p = 0.0003
Table 3 Comparison of immune dysregulation between bacterial sepsis and tuberculosis
Bacterial Sepsis Malawian TB Patients
↓monocyte HLA-DR expression associated with secondary infection [2, 4] Variable monocyte HLA-DR expressiona
HLA-DR expression correlates with TNFα production [24] No correlation between monocyte HLA-DR expression and
TNFα production
Correlation between monocyte HLA-DR and CD86 expression [6, 25] Correlation between monocyte HLA-DR and CD86 expression
↓CD86 expression associated with increased severity of inflammation [7, 25] Widely variable monocyte CD86 expressiona
Expansion of CD14loCD16hi monocyte population [26] Expansion of CD14loCD16hi monocyte population
CD14loCD16hi monocytes major TNFα producers [11] ‘Classical’ CD14hiCD16neg monocytes major TNFα producers
aSample size insufficient to correlate with clinical outcome
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downstream processes involving the adaptor molecule
MyD88 may be of greater clinical relevance [21, 22]. Our
findings are consistent with this hypothesis, suggesting the
occurrence of a generalised dysfunction of TLR signalling
rather than a defect in a specific receptor pathway. Con-
versely, a recent genome-wide association study conducted
in a healthy Caucasian population identified the TLR10/1/6
locus as dominant common genetic factor influencing
inter-individual variability in TLR-induced whole blood re-
sponses [23]; the significance of this in human disease
states warrants further evaluation. Table 3 summarises the
key differences between our findings in TB patients and
those which have been reported in patients with sepsis.
Limitations
This study was limited by the identification of only 22 pa-
tients who died or had a life-threatening event during the
intensive phase of TB treatment. However, this study was
able to investigate both serum and antigen-induced cytokine
responses in association with clinical outcome in a longitu-
dinal cohort of TB patients containing both HIV positive
and negative individuals, in contrast with previous studies
which have tended to be cross sectional and more specific
in their inclusion criteria. Additionally, the small number of
patients included in the flow cytometric analysis precluded
correlation with clinical outcome; this was unavoidable as
these analyses could not be performed on stored samples.
Nonetheless, the results presented here will inform the
design of larger prospective immunological studies.
Conclusions
Malawian adults who clinically deteriorated during the
intensive phase of TB treatment had trends towards
lower monocyte derived cytokine responses (IL1β, TNFα
and IL7) to antigenic stimulation than matched patients
with good clinical outcome. Although validation of these
findings in an unrelated cohort of TB patients from an-
other setting is necessary, our data suggest this relates to
a generalised down-regulation of TLR signalling pathways
rather than a defect in a specific receptor. Further work
investigating these pathways may help explain the vulner-
ability to superadded infection which is a major cause of
poor clinical outcome in this population.
Additional files
Additional file 1: Table S1. Median and IQR for responses to stimulation
with heat killed Mycobacterium Tuberculosis (H37Rv) or Lipopolysaccaride
(LPS). P-values are derived from Mann-Whitney U tests. 11 analyses were
performed for each stimulus, giving a corrected p value of 0.0045 using the
Bonferroni correction. (DOCX 17 kb)
Additional file 2: Figure S1. Gating strategy to identify monocyte
populations. The first plot represents the forward scatter- side scatter
characteristics and the second the separation according to CD14 and
CD16 staining. (JPEG 61 kb)
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